Literature DB >> 8253531

Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.

R Stein1, A Basu, S Chen, L B Shih, D M Goldenberg.   

Abstract

The murine monoclonal antibody (MAb) RS7-3G11 is an IgG1 with pancarcinoma reactivity, which has been raised against human squamous-cell carcinoma of the lung. Immunoperoxidase staining of frozen tissue sections demonstrated that the antigen defined by RS7-3G11 is present in tumors of the lung, stomach, bladder, breast, ovary, uterus and prostate. The rate and extent of internalization of RS7-3G11 into Calu-3, an adenocarcinoma of the lung cell line, was investigated using unconjugated MAb, followed by fluorescence labelling, and by binding 125I-RS7-3G11 followed by acid removal of surface-bound antibody. Rapid internalization of MAb RS7-3G11 into target cells was observed. Antibody internalization was noted at 30 min, and by 2 hr virtually all MAb RS7-3G11 was internal. Although MAb RS7-3G11 was raised against non-small-cell carcinoma of the lung, ME-180, a cervical-carcinoma cell line, expresses higher quantities of the antigen than the lung-carcinoma cell lines. Due to the higher antigen density in ME-180 cells, this line was used for immunoprecipitation studies and antigen purification. Immunoprecipitation studies using the ME-180 cervical-carcinoma cell line metabolically labeled with [3H]leucine or [3H]glucosamine demonstrated that the antigen defined by RS7-3G11 is a glycoprotein of M(r) 46 kDa. Deglycosylation by treatment with endoglycosidase-F resulted in a protein with a M(r) of 35 kDa. RS7-3G11-antigen was purified from ME-180 tissue-culture cells using affinity-column chromatography. By SDS-PAGE it was seen that the antigen was highly purified. The major band appeared at M(r) of 45 to 48 kDa. This result is in agreement with the immunoprecipitation studies. The broad band observed in the SDS-PAGE is typical of many glycoproteins, and suggests heterogeneity of glycosylation. Chemical and enzymatic treatments of the antigen, followed by Western blot analyses, suggest that the RS7-3G11 antigenic determinant is composed of a conformation-dependent peptide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253531     DOI: 10.1002/ijc.2910550611

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

2.  Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Natalia Buza; Sergio Pecorelli; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2011-07-13       Impact factor: 8.661

3.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

4.  First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Authors:  Alexander N Starodub; Allyson J Ocean; Manish A Shah; Michael J Guarino; Vincent J Picozzi; Linda T Vahdat; Sajeve S Thomas; Serengulam V Govindan; Pius P Maliakal; William A Wegener; Steven A Hamburger; Robert M Sharkey; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2015-05-05       Impact factor: 12.531

5.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

Authors:  Joyce Varughese; Emiliano Cocco; Stefania Bellone; Marta Bellone; Paola Todeschini; Luisa Carrara; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2011-03-30       Impact factor: 5.482

7.  Identification and characterization of a novel TACSTD2 mutation in gelatinous drop-like corneal dystrophy.

Authors:  Preeti Paliwal; Jaya Gupta; Radhika Tandon; Namrata Sharma; Jeewan S Titiyal; Seema Kashyap; Seema Sen; Punit Kaur; Divya Dube; Arundhati Sharma; Rasik B Vajpayee
Journal:  Mol Vis       Date:  2010-04-28       Impact factor: 2.367

8.  Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.

Authors:  Catharina M van Rij; Susanne Lütje; Cathelijne Frielink; Robert M Sharkey; David M Goldenberg; Gerben M Franssen; William J McBride; Edmund A Rossi; Wim J G Oyen; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

9.  TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Authors:  Shanglei Ning; Sen Guo; Jianjun Xie; Yunfei Xu; Xiaofei Lu; Yuxin Chen
Journal:  J Gastrointest Surg       Date:  2012-12-01       Impact factor: 3.452

Review 10.  Characteristics of corneal dystrophies: a review from clinical, histological and genetic perspectives.

Authors:  Ze-Nan Lin; Jie Chen; Hong-Ping Cui
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.